
SKIN Stock Forecast & Price Target
SKIN Analyst Ratings
Bulls say
SkinHealth Systems is facing near-term headwinds, including revised revenue guidance for 2026 due to continued device sales weakness, increased competition from knockoffs and scaled down models, and slow stabilization of system sales. However, the company's new CEO is taking proactive measures to address these challenges, including hiring a new head of sales and developing a new Hydrafacial model for launch in 2028. Furthermore, SkinHealth Systems's 4Q results showed strong performance with sales and gross margin beating expectations and growth in consumable sales. Despite macroeconomic risks and competition, the company's strong brand reputation and high-quality products position it well for long-term success in the global skincare and aesthetics market.
Bears say
SkinHealth Systems is facing multiple ongoing legal obligations, including shareholder derivative lawsuits and patent infringement cases, which may continue to negatively impact cash flow. Additionally, one of the company's key patents is set to expire in 2026, and they have been aggressively defending it from counterfeit manufacturers. While they reported strong numbers in their 1Q earnings, their net leverage remains high and they are still facing challenges in certain regions and with device utilization. Furthermore, potential impediments to their stock price target include softening equipment demand and an inability to reduce operating expenses, as well as regulatory risks faced by their products.
This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.
SKIN Analyst Forecast & Price Prediction
Start investing in SKIN
Order type
Buy in
Order amount
Est. shares
0 shares